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                                                              ABSTRACT 
 
Mandke, Pooja M.S Department of Biochemistry and Molecular Biology, Wright State 
University, 2012. Study of microRNA-34a mediated post transcriptional regulation of 
MDM4 
 
 
MDM4  is  an  important  negative  regulator  of  the  tumor  suppressor  p53.  In normal 
unstressed cells the activity of p53 is kept under control by MDM4 and its homologue 
MDM2.  MDM4  is  said  to  possess  oncogenic  potential  based  on  the  evidence  of  its 
overexpression in many cancers. Until recently it was believed MDM4 is constitutively 
transcribed; however a decrease in full length MDM4 in response to genotoxic stress was 
observed paving way for exploring the mechanism responsible for this. 
 
It was observed miR-34a a member of the miR34 family which is a direct transcriptional 
targets  of  p53  could  have  a  potential  role  in  regulation  of  MDM4  expression.  The 
3’untranslated region of MDM4 was also seen to contain several miR-34a binding sites. 
 
However reporter assays with select regions of the 3’UTR revealed that the 3’UTR was 
unresponsive t o  m i R -34a  mediated  regulation.  Reassessment o f   the  MDM4  gene 
revealed presence of a potential miR-34a regulatory site in the protein coding exon 11 of 
MDM4. This site was further considered to check for functionality in response to miR- 
34a  modulation.  A  reporter  with  the  miR-34a  site  from  the  coding  region  was 
constructed. This reporter was responsive to overexpression or inhibition of endogenous 
miR-34a in H1299 and MCF7 cells respectively ascertaining the functionality of this site. 
iv 
 
A SNP leading to A<C transversion in the seed region of this miR-34a site in the exon 11 
was predicted to disrupt responsiveness to miR-34a. We confirmed this by creating point 
mutants and performing reporter assays. 
This study was designed to understand the regulation of MDM4 in absence of DNA 
damage conditions. Understanding the role of miR-34a in regulation of MDM4 will pave way 
for  designing  specific therapeutic strategy for reactivation of p53 via inhibition of 
MDM4 in cancer that overexpress MDM4 and retain wild type p53. 
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I. INTRODUCTION 
 
 P53, MDM2 and MDM4 
 
The gene TP53, encoding transcription factor p53, is one of the most important tumor 
suppressors and is considered as the guardian of the genome (Efeyan 2007). As a part of 
its overall function it is shown to play a role in providing protection against malignant 
transformation and maintenance of genomic stability. The crucial role of p53 as a tumor 
suppressor is demonstrated by the fact that it is seen to be mutated or deleted in more 
than fifty percent of the human cancers. However, in cancers which possess wild type 
p53, p53 inactivation can result from the amplification/overexpression of its specific 
inhibitors MDM2 and MDM4 (also known as MDMX) (Toledo 2007). 
In normal unstressed cells p53 is maintained at basal levels by the p53 binding proteins 
MDM2 and MDM4. MDM2 (transformed mouse 3T3 cell double minute 2) is a well-
studied regulator/inhibitor of p53. MDM2 affects subcellular localization of p53 where it 
promotes monoubiquitination of p53 in nucleus thereby leading to its nuclear export. In 
the cytoplasm more ubiquitin is added to this mono ubiquitin which facilitates 
degradation of p53 (O‟Keefe 2003). MDM2 indirectly also affects translation of p53 via 
binding to the ribosomal protein L26. Under conditions of stress L26 binds to the 5‟ 
untranslated region of p53 mRNA and increases translation of p53 mRNA leading to 
production of more p53 protein. MDM2 however is shown to interact with L26 and 
target it for ubiquitin mediated proteasomal degradation causing a decrease in the L26 
mediated increase in p53 translation (Ofir Rosenfeld 2008). MDM4 also affects stability 
and transcriptional activity of p53 protein. MDM2-dependent p53 inhibition is essential 
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in regulating p53 activity during embryonic development and in adult tissues (Wang 
2012). MDM2 regulates the p53 turnover by binding p53 and acting as a ubiquitin E3 
ligase mediating the proteasomal degradation of p53.  It is seen that MDM2 abrogates 
the ability of p53 to induce cell cycle arrest and apoptosis by virtue of its overexpression. 
Its overexpression as a result of gene amplifications is seen in about 30% of human 
osteogenic sarcomas and soft tissue sarcomas (Chen 1998). In tumors where MDM2 is 
not amplified, p53 inactivation can also take place as a result of  hyperactivation of 
MDM2 due to silencing of ARF expression (Hu 2006). Therefore, MDM2 is a key factor 
in tolerance of wild type p53 in nearly 50% of tumors, making it an attractive target for 
the development of novel anti-tumor agents (Bond 2005). 
Murine Mdm4 (for transformed mouse 3T3 cell double minute 4, also Mdmx) and 
human ortholog MDM4 (also HDMX) are the closest analogues of Mdm2 
(transformed mouse 3T3 cell double minute 2). MDM4 shares a considerable sequence 
homology with MDM2 and is also structurally analogous to MDM2. Like MDM2, MDM4 
possesses a p53-binding domain (p53BD) encompassing approximately the first 100 
amino acids, the residues required for p53 interaction are conserved in both MDM2 and 
MDM4 and the same residues in p53 are required for its interaction with both MDM2 
and MDM4. It also has a C-terminus RING (really interesting new gene) finger region 
through which it interacts with MDM2 (Marine 2006, Mancini 2010). 
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Figure 1: Schematic representation of domain structures of Mdm2, 
Mdm4 (MdmX) and p53 adapted from Waning D, Lehman J, Batuello C, 
and Mayo L (2010) Controlling the Mdm2-Mdmx-p53 Circuit. 
Pharmaceuticals, 3(5): 1576–1593. 
 
MDM4 is also an essential inhibitor of p53 in vivo. Although structurally homologous to 
MDM2, MDM4 does not possess the intrinsic ubiquitin ligase activity hence does not 
directly participate in degradation of p53 protein. However, MDM4 stimulates the 
MDM2 mediated ubiqutination and degradation of p53 by binding to MDM2 through C-
terminal RING domain. The ubiquitin ligase MDM2 also ubiqutinates and targets 
MDMX for degradation via MDM4-MDM2 RING domain interaction; and this may be an 
important mechanism for elimination of MDM4 during DNA damage (Tanimura 1999, 
Hu 2006). Recent advances in the field from biochemical and genetic studies have 
revealed an essential role for the MDM4 RING domain in MDM2-dependent p53 
polyubiquitination and degradation. MDM2 on its own is a monoubiquitin E3 ligase for 
p53, but is converted to a p53 polyubiquitin E3 ligase by MDM4 through their RING-
RING domain interactions. MDM4 acts as an activator as well as a substrate 
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of MDM2/MDM4 E3 complex (Wang 2012). Apart from its indirect role in maintaining 
p53 protein levels MDM4 is shown to control the transcriptional activity of p53 by 
binding to its N terminal domain. Genetic studies have shown that MDM4 controls p53 
transcriptional activity independent of MDM2 (Francoz 2006). 
 
Like MDM2, MDM4 is overexpressed in many cancers, especially those of breast, colon, 
and lung, as well as in glioma, lymphoma, and retinoblastoma (Danovi 2004), where it is 
thought to promote tumorigenesis by suppressing p53 function. However, conditional 
deletion (Grier 2006) and knockout studies (Parant 2001) have shown that MDM4 like 
MDM2 , is required for protection against p53 lethal activity in embryonic development. 
This indicates a unique role of MDM4 in regulating p53 during embryonic development 
(Migliorini 2002). Although MDM4 can regulate p53 stability by heterodimerization 
with MDM2, its impact on p53 level is moderate compared to MDM2. Recent studies 
suggest that the major mechanism of p53 regulation by MDM4 is the formation of 
inactive p53-MDM4 complexes. Therefore, elimination of MDM4 is important for 
efficient p53 activation during stress response (Gilkes 2008). 
 
Regulation of MDM4 
 
As stated earlier, MDM4 is a critical negative regulator of p53 and keeps its activity in 
check in normal unstressed cells. However, under conditions of stress which requires the 
activation of p53, it is necessary to control/inhibit activity of the negative regulators of 
p53 viz.MDM2 and MDM4. MDM4 expression can be controlled at the level of 
transcription, post transcription, translation or post translation which may lead to either 
overexpresssion as seen in some cancers or inhibition of expression. The transcription 
control of MDM4 is an area less explored. The changes in production of transcripts of 
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MDM4 could not be attributed to changes promoter activity of MDM4 (Markey 2008). 
However, there are reports of MDM4 expression being regulated by mitogenic signaling 
pathways via binding of different transcription factors to the MDM4 promoter. This 
mechanism may confer protection to normal proliferating cells from p53 but may 
contribute to hampering of p53 response during tumor development (Gilkes 2008). It 
was also seen that a transcript variant of MDM4 also known as HDMX could be 
transcribed from a p53 responsive promoter in the first intron of the HDMX gene. This 
variant transcript called as HDMX-L was more efficiently translated than the transcript 
produced from the constitutive promoter P1 of HDMX gene and produced a functional 
protein product (Philips 2010).  
Another aspect playing a role in controlling expression of full length MDM4 could be 
production of alternative splice variants in response to damage conditions as reported in 
some cancers (Mancini 2009).  The production of alternative splice variants also initiates 
another layer of p53 regulation. Some of the reported splice variants of MDM4 are the 
XALT1 which lacks the p53-binding domain and retains the COOH-terminal RING 
domain. The XALT2 splice variant in which only retains the p53 binding domain in the 
final protein. The MDM4211 variant is a highly aberrant form present only in tumor 
cells. The MDM4-A, MDM4-G and MDM4-S variants are also seen in certain cancers 
(Figure 2). The XALT2 variant which lacks the p53 binding domain may be responsible 
for negatively regulating the full length MDM4 variant (Chandler 2006) however the 
presence of XALT2 does not completely compensate for the loss of full length MDM4 
variant (Markey 2008). On the other hand the XALT1 variant has only the p53 binding 
domain hence these two variants may function in an antagonistic manner in the cell 
(Chandler 2006). 
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Figure 2: MDM4 and its splice variants A) schematic of full length MDM4 
B) Splice variants of MDM4 
Mancini F et al (2009) MDM4 (MDMX) and its transcript variants Current 
Genomics 10: 42-50  
 
There are also reports on the control of absolute stability of MDM4 mRNA which could 
possibly be due to the role of microRNAs (Markey 2008). At the level of translation, the 
role of eukaryotic initiation factor factor 4E and 4E-BP1 could play a role in affecting the 
translation of MDM4 protein (Zhu 2005, Horton 2002); however no other reports are 
available implicating the process of translation itself. MDM4 protein itself is subject to 
MDM2 E3 ligase mediated proteasomal degradation as a result of phosphorylation 
signals (Chen 2005). Against the background of various aspects controlling MDM4 
expression and activity, the area of post transcriptional control of MDM4 is interesting 
and one that remains less explored.  
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Potential Role of microRNAs in regulation of MDM4 
 
What are microRNAs? 
 
MicroRNAs (miRNAs) are highly conserved, endogenously expressed, non-protein-
coding RNAs that play a role in regulation of  gene expression. These are typically 20-25 
nucleotide long and regulate gene expression in plants and animals by recognizing 
motifs of imperfect complementarity between the mature microRNA via a 2-7 bases  
region  called a  „seed region‟ and 3‟ untranslated region (UTR) of target transcripts.  
miRNA mediate regulation of gene expression by repression of translation, degradation 
of mRNA and mRNA decay initiated by miRNA-guided rapid deadenylation (Zhang 
2007).  Since the discovery of miRNAs a large number of miRNAs have been discovered 
and these are shown to participate in variety of homeostatic processes such as 
development, differentiation, cell proliferation and cell death. Since miRNAs are 
involved is all the important cellular processes their dysregulation has been linked to 
initiation and progression of cancer. Hence depending on the genes they regulate and the 
pathways they affect miRNAs can be termed as oncogenes or tumor supressors (Lyamm-
lennon 2009). 
 
Biogenesis of microRNAs.  
miRNA genes are transcribed by RNA polymerase II . The resulting transcript is capped 
with a specially modified nucleotide at the 5‟ end and polyadenylated with multiple 
adenosines at the 3‟end. This primary miRNA (pri-miRNA) varies from 200 nt to several 
kb. The Drosha ribonuclease  in conjunction with DiGeorge Syndrome Critical Region 
Gene 8 (DGCR8), cleaves the pri-miRNA into a 60- to 70-nt precursor-miRNA (pre-
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miRNA). Pre-miRNA hairpins are exported from the nucleus to the cytoplasm by 
Exportin-5 and Ran-GTP. In the cytoplasm, the pre-miRNA hairpin is cleaved by the 
enzyme Dicer with the TAR RNA-binding protein (TARP) or PKR activating protein 
(PACT). One miRNA strand, the guide miRNA, is taken into the RNA-induced silencing 
complex (RISC), of which the Argonaute proteins are a main component. In particular, 
Argonaute 2 (Ago2) is thought to play a central role in the miRNA biogenesis pathway. 
In the RISC, the guide miRNA finds and binds its complementary target mRNA. miRNAs 
that bind to mRNA targets with perfect matching induce mRNA degradation, whereas 
translational repression is induced when matching is imperfect (Lee 2004, Shomron 
2009). 
 
Figure 3: MicroRNA biogenesis   
Nohata N, Hanazawa T, Kinoshita T,  Okamoto Y, Seki N  (2012) MicroRNAs 
function as tumor suppressors or oncogenes: Aberrant expression of 
microRNAs in head and neck squamous cell carcinoma. Elsivier ANL-1683; 1-7  
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MicroRNAs in cancer 
After the discovery of miRNAs several observations led researchers to believe that 
miRNAs could play a role in cancer. In C. elegans and Drosophila where the earliest 
miRNAs were discovered they were shown to be associated with functions like cell 
proliferation and apoptosis (Ambros 2003), suggesting that their dysregulation may 
pave way for proliferative diseases like cancer. Secondly, it was seen that more than half 
the miRNA genes were located on sites on the genome that were frequently amplified or 
deleted in human cancers (Calin 2004). Thirdly, compared with normal tissue, 
malignant tumors and tumor cell lines were found to have widespread deregulated 
miRNA expression (Lu 2005). However the question that remained to be answered was 
whether malignant transformation was a consequence or cause of altered miRNA 
expression. 
Further studies showed miRNAs were directly involved in human cancers, including 
lung, breast, brain, liver, colon cancer, and leukemia (Nikitina 2012). Depending on the 
genes they target and the pathways they affect miRNAs may function as oncogenes or 
tumor suppressors. For instance microRNAs such as mir-17-92, have oncogenic potential 
owing to its presence in a region on chromosome 13 commonly amplified in human B-
cell lymphoma. On the other hand miRNAs such as let-7 are shown to possess tumor 
suppressive potential as it is able to inhibit RAS expression in human cancer cell lines 
(Johnson 2005). Hence against this background, expression profiles of miRNAs may not 
only serve as important biomarkers for diagnosis of cancer but also aid in development 
of probable therapeutics for cancer prevention (Sassen 2008, Nohata 2012). 
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MiR-34 family and p53 
As mentioned earlier p53 is an important tumor suppressor. P53 functions as a tumor 
suppressor by transcriptionally activating its target genes viz genes involved in cell cycle 
checkpoints, apoptosis and cellular senescence.  However, against the background of the 
tumor suppressive function of p53 the concept of p53 mediated repression of target 
genes was less appreciated. A proof for this was provided by a study which showed p53 
mediated downregulation of a new set of genes indicating p53 induces cell cycle arrest 
not only by transactivation of cell cycle inhibitors (p21) but also through repression of 
targets regulating proliferation at different phases of the cell cycle (Spurgers 2006 ). A 
plausible explanation was provided by the existence of microRNAs. It was possible that 
p53 was mediating indirect control of certain target genes at post transcriptional level via 
influencing expression of microRNAs (Feng 2011). 
In 2007 reports showed that miR34 family members are direct transcriptional targets of 
p53 and might be key effectors of p53 tumor suppressor function (Bommer 2007).  The 
miR34 family consists of 3 members: mir-34a, miR-34b and miR-34c. The miR-34a is 
transcribed from an independent transcript and is ubiquitously expressed with high 
expression in the brain tissue. The miR-34b and miR-34c share a common primary 
transcript and are predominantly expressed in the lung tissue. Reports have shown that 
miR34a and miR-34b/c are downregulated in many cancers.  Apart from the 
confirmation of miR34a being a direct transcriptional direct of p53 its importance in p53 
mediated functions was confirmed by demonstration of induction of apoptosis upon 
overexpression of miR34a (Hermeking 2010). 
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Figure 4: The miR-34 family as mediator of tumor suppression by p53. 
Hermeking H (2010) MiR-34 family in cancer and apoptosis Cell Death and 
Differentiation 17, 193–199 
miR-34a was shown to target and repress SIRT1  an NAD-dependent deacetylase, which 
is known to inhibit several pro-apoptotic proteins including p53. Apoptosis induced by 
the re-introduction of miR-34a is seen to be p53 dependent and linked to the targeting of 
SIRT1 mRNA by miR-34a. Hence it can be said the regulation of SIRT1 by miR-34a is 
part of a positive feedback loop that leads to further activation of p53. Another feedback 
loop between p53 and miR-34a may involve the downregulation of the p53-inhibitor 
HDMX by miR-34a. Hence miR-34a is reported to be an important mediator of p53 
tumor suppressive function (Hermeking 2010). 
 
MicroRNAs as therapeutics? 
Since miRNAs are linked to various aspects of cancer progression and pathogenesis. 
miRNA based therapeutic approaches have tremendous potential to produce cancer 
specific effects. Inhibition of oncogenic miRNAs or overexpression of tumor suppressive 
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miRNAs may help control malignant transformation. Hence that is an exciting aspect of 
miRNA  biology . 
As already stated with respect to p53, the miR-34 family has gained much attention and 
is seen to be down regulated in many cancers. Recent research has shown that miR-34 
based therapy could be of great value. Studies have shown that impairment of 
tumorigenesis was seen in a xenograft model of non-small lung cancer with an 
intratumor or systemic administration of miR34 mimic and same was observed in case 
of  lung tumors (Trang 2011). As it is already known attenuated expression of miR34 is 
observed in prostate and pancreatic cancers it could prove to be a valuable therapeutic 
approach for these cancers (Pramanik 2011, Liu 2011). 
 
Inhibition of MDM4 and MDM2 as possible therapeutic strategies 
MDM4 is overexpressed in many cancers and this acts to block the p53 tumor 
suppressive function. Hence, inhibition of MDM4 in cancers that retain wild type p53 
may have therapeutic potential. Currently there are therapeutic strategies involving 
inhibition of MDM2 but response to these may be dampened in the presence of high 
levels of MDM4, hence this calls for MDM4 specific therapeutic strategies (Wade 2009). 
However, the effect of acute systemic inhibition of MDM4 on normal adult tissues had to 
be explored. A study in this direction showed that MDM4 was required to buffer p53 
activity in adult normal tissues and their stem cells. Another important observation was 
that transient restoration of p53 in absence of MDM4 was not lethal and had no 
phenotypic consequences. As opposed to restoration of p53 in a MDM2 null background 
which led to p53 dependent cell death (Gembraska 2012). It was also shown that the 
therapeutic impact of restoring p53 in a tumor model is enhanced in the absence of 
MDM4, leading to a significant extension of survival over p53 restoration in the presence 
of MDM4. Hence, systemic inhibition of MDM4 is both a feasible and safer therapeutic 
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strategy for restoring p53 function in tumors that retain wild-type p53 than inhibition of 
Mdm2 (Garcia 2011, Gembraska 2012). 
Some of the recent advances for targeted therapy for MDM4 is the development of 
(stapled alpha helix peptide) SAH-p53-8. The design of the SAH-p53-8 was based on the 
peptide sequence of the alpha helix transactivation domain of p53. This was previously 
designed for targeting MDM2 however studies showed 25-fold greater binding 
preference of SAH-p53-8 for HDMX. The mechanism of action of SAH-p53-8 involves 
blocking formation of the p53-HDMX interaction, and thereby restoring the p53 
pathway, as seen by reduction in tumor cell viability and transcriptional upregulation of 
p53 targets. SAH-p53-8 was particularly effective in nutlin resistant tumors. Thus, 
cancers that sequester p53 via HDMX overexpression may be particularly sensitive to 
SAH-p53-8 or other HDMX-specific antagonists in development (Bernel 2010). 
 
Objective 
The objective of this study was to explore the role of miR-34a as a possible factor 
responsible for downregulation of MDM4 in absence of DNA damage. It was previously 
seen that in presence of DNA damage there was decrease in full length MDM4 
transcripts. However the mechanism of this downregulation was not exactly understood. 
Since there was a decrease in the full length transcripts it was indicative of certain 
transcriptional or post transcriptional regulatory mechanisms. After, preliminary 
evidence of MDM4 as a potential target of miR-34a as seen through computational 
analysis; we sought to explore the role of miR-34a in regulation of MDM4. We 
hypothesized that miR-34a did regulate the expression of MDM4.  Firstly qPCR and 
western blot analysis was done to assess response of endogenous MDM4 to miR-34a as 
compared to known targets of miR-34a. This was followed up by reporter assays with 
plasmids containing potential miR-34a target sites from MDM4 tested in background of 
14 
 
elevated or inhibited levels of miR-34a to confirm functionality of these miR-34a target 
sites in MDM4. The results obtained from this study will help in the understanding of the 
regulation of MDM4 by miR-34a paving way for its potential use as a therapeutic 
strategy for MDM4 inhibition. 
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II. MATERIALS AND METHODS 
Cell Culture 
Human non-small cell lung carcinoma cell line H1299 was cultured in Dulbecco‟s 
modified Eagle‟s medium (DMEM, Atlanta Biologicals) supplemented with 10% normal 
calf serum.  Breast cancer cell line MCF7, human fibroblasts IMR90, and osteosarcoma 
cell line SAOS2 were cultured in DMEM supplemented with 10% fetal calf serum.  All cell 
lines were obtained from the American Type Culture Collection.   
Quantitative RT-PCR  
MCF7 cells were transfected 48 hours after seeding (2 x 105) cells in 6 cm plates.  Thirty 
nanomolar  miRVANA hsa-miR-34a inhibitor (Ambion) was added to 50 µl of serum free 
media. Six l lipofectamine 2000 was added to 50 l serum free media. The two 
solutions were mixed in equal quantities and allowed to stand at room temperature for 
20 minutes. Hundred l of the resulting solution was added to 6 cm plates containing 2.9 
ml serum free media. After 5 hours of incubation the cultures were returned to DMEM 
media containing 10% serum. Forty eight hours later the cultures were processed for 
RNA extraction.  
RNA extraction 
Cells were washed with phosphate buffered saline (PBS). This was followed by addition 
of TRIzol reagent (Invitrogen), a mixture of phenol, guanidine isothiocynate, red dye and 
other proprietary components that can be used to isolate RNA. The cells were scraped, 
collected in a centrifuge tube and passed through a syringe. This was incubated at room 
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temperature for 5 minutes followed by addition of 200 µl of chloroform, shaking the 
contents for 15 seconds and incubation at room temperature for 2-3 minutes. The 
contents were centrifuged at 12,000g for 15 minutes at 4oC. This resulted in separation of 
an aqueous and organic phase. The aqueous phase was transferred to a new tube and 5 
µg of glycogen was added to it. To this was added 500 µl isopropyl alcohol, incubated at 
room temperature for 10 minutes and centrifuged at 12,000g for 10 minutes at 4oC. The 
supernatant was removed and the pellet was washed with 1ml of 75% RNase free ethanol 
and centrifuged at 7500g for 5 minutes at 4oC. The supernatant was again removed and 
the pellet was air dried for 5-10 minutes. The pellet contained RNA which was re 
suspended in 40 µl of RNase free water and incubated at 55-60oC for 1o minutes. 
Following this RNA was either stored at -80oC for future use or continued for 
quantification by Nanodrop ND-1000 spectrophotometer. The absorbance ratio at 
260nm and 280nm was considered to determine purity of RNA, with a ratio between 
1.8-2.1 was considered as optimum. 
MicroRNA extraction 
RNA extraction was carried out using the TRIzol reagent method as mentioned above. 
The RNA obtained by this method was further processed to enrich for microRNA using 
the RT2qPCR Grade miRNA Isolation Kit (SAbiosciences) according to manufacturer‟s 
protocol. 
Reverse transcription of total RNA 
0.5 µg of RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). The RNA was mixed with water to bring the final 
volume to 9.62 µl. For one reaction the reaction mix was prepared as follows: 
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Content Volume µl (x 1) 
10X Taqman RT buffer 2.5 
25mM MgCl2 5.5 
deoxyNTPs 5 
random hexamers 1.25 
RNase inhibitor 0.5 
Multiscribe reverse transcriptase 50U/µl 0.625 
Total volume 15.38 
 
The contents of the reaction mix were tapped gently to mix properly and spun to 
eliminate bubbles. The reaction mix was added to 0.2 ml microamp tubes followed by 
addition of 9.62 µl RNA sample (total reaction volume 25 µl). The contents of the tube 
were tapped gently to mix properly and spun to eliminate bubbles. The reaction was 
incubated at 25oC for 10 minutes, 48oC for 30 minutes and 95oC for 5 minutes and held 
indefinitely at 4oC. The cDNA was diluted to 1ooµl prior to quantitative PCR. 
Reverse transcription of microRNA 
10 ng of the microRNA was reverse transcribed using miRNA-specific primers for hsa-
miR-34a or hsa-mir213 (to normalize) (5X working stock solution) according to the 
TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems).  
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The master mix was prepared as follows: 
Components Volume µl (x1) 
10X Reverse transcription buffer 1.5 
100mM dNTPs 0.15 
RNase inhibitor 20U/µl 0.19 
multiscribe reverse transcriptase 50U/µl 1 
Nuclease free water 4.16 
Total volume 7 
 
The final reaction was set with 7 µl of master mix and 5 µl of RNA (total quantity 10 
ng).The contents were mixed gently and centrifuged. Meanwhile the primer tubes were 
thawed on ice, mixed by vortexing and centrifuged before addition to the reaction 
mixture. This 12 µl mixture was added to two different tubes followed by addition of 3 µl 
of 5X primers specific to miR-34a in one and miR-213 in another. These tubes were 
incubated at 160C for 30 minutes, 420C for 30 minutes, 850C for 5 minutes and held at 
40C indefinitely. The cDNA was diluted to 50 µl prior to quantitative PCR. 
Quantitavtive RT-PCR 
The cDNA from both the total RNA and microRNA was used to perform quantitative RT-
PCR. For this purpose 9 µl of the diluted cDNA was mixed with 11 µl of  the mastermix 
which contains 10 µl of the 2X Taqman universal master mix (no AmpErase, Applied 
Biosystems) and 1 µl of the 20X of the Assay on Demand gene expression product 
(Applied Biosystems) for MDM4,CDK6, CCND1, GAPDH, miR-34a and miR-213. Four 
technical replicates of each sample were set up. The reactions were incubated at 950C for 
10 minutes followed by 40 cycles of 950C for 15 seconds and 600C for 1minute. Target 
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gene expression from RNA was normalized to GAPDH and from microRNA was 
normalized to miR-213. SDS 2.2.2 software was used for target gene expression analysis 
with setting automatic Ct values, outlier removal and 95% confidence interval for RQ 
min/max calculations. All the reactions were performed in the ABI 7900HT sequence 
detection system (Applied Biosystems). 
Reporter Assays 
H1299 cells were transfected 24 hours after seeding (2.5 x 106) cells in 6 cm plates. The 
psicheck2 vector or psicheck2-ex11 reporter or psichcheck2-ex11 A>C reporter, and mir-
34a expression plasmid or mir-34a-mut expression plasmid, were added to serum free 
media (final volume of 200 l). Six l of lipofectamine2000 was added to 200 l of 
serum free media, which was then mixed with the plasmid DNA and incubated 30 
minutes at room temperature.  400 l of the resulting DNA:lipid solutions were added to 
cells on 6 cm plates containing 2.5 ml serum free media. After 5 hours of incubation the 
cultures were replaced with DMEM media containing 10% NCS. 24 hours later the 
cultures were processed for the dual luciferase assay using the Promega Dual Luciferase 
assay system and protocol.  Samples were normalized to luciferase expression in the 
vector-transfected cells.  Paired, one-tailed t-tests were used to determine significance.  
The plasmid psicheck2-AS34a contains a consensus response site for miR-34a, and was 
used as a positive control for response to miR-34a overexpression or inhibition.   
MCF7 cells were transfected 24 hours after seeding the 24-well plates (4 x 104 cells/ 
well).  The reporter plasmid (0.2 g) with or without the hsa-miR-34a inhibitor (30 nM) 
and the psicheck2 (vector) plasmid (0.2 g) with or without the inhibitor (30 nM) were 
added to 50 l of serum free DMEM media. Two l of lipofectamine2000 was added to 
50 l serum free DMEM media. The two solutions were mixed in equal quantities and 
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allowed to stand at room temperature for 20 minutes. 100 l of the resulting DNA:lipid 
solution was added to culture plates containing 2.9 ml serum free media. After 5 hours of 
incubation the serum free media was replaced with DMEM media containing 10% FBS. 
24 hours later the cells were processed for the Dual Luciferase assay (Promega). 
The Dual-Luciferase reporter (DLR) assay system provides an efficient means of 
performing dual reporter assays. In the DLR assay, the activities of firefly viz hluc 
(Photinus pyralis) and renilla viz. Rluc (Renilla reniformis, also known as sea pansy) 
luciferases are measured sequentially from a single sample. This is achieved as both the 
renilla (experimental reporter) and firefly luciferase (control reporter) genes are present 
on the same plasmid. 
The cells on the plate were first cleared of any growth media and washed with phosphate 
buffered saline (PBS). IX passive lysis buffer (PLB) was added to plate according to the 
plate/well size. The culture vessel was gently rocked at room temperature and 
transferred to a vial or tube. For the assay the firefly luciferase reporter was measured 
first by adding 100 µl luciferase assay reagent II (LAR II) to 20 µl of the lysate. After 
quantifying the firefly luminescence, this reaction was quenched, and the renilla 
luciferase reaction was initiated by simultaneously adding stop & glow reagent to the 
same tube. The luminometer was used to quantify the luminescence generated from the 
two steps. The ratio of renilla luciferase to firefly luciferase was the calculated to give 
relative luciferase activity. Readings from six biological replicates of the same 
experiment were obtained and the average of these are plotted to obtain the average 
relative luciferase expression for each experimental condition. 
Immunoblotting 
MCF7 cells were transfected 24 hours after seeding the 6 cm plates (2 x 104 cells) and 
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treated with 30 nM miRVANA hsa-miR-34a inhibitor (Ambion) as described above. 48 
hours later the cells were processed for protein extraction. 
The cells were harvested from the 6 cm plates in phosphate buffer saline (PBS) and lysed 
in RIPA buffer (50 mM Tris pH=8.0, 150 mM NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1% 
SDS) (150 µl) to which was added protease inhibitor cocktail PIC (1 l/100 l) and NaF 
(to 50 M). The contents were mixed by pipeting, incubated on ice for 30 minutes and 
centrifuged at 10,000 rpm for 5 minutes at 4oC. The supernatant was then taken and 
protein concentration measured using the Bradford Protein Assay (Biorad). The proteins 
were separated by SDS-PAGE. After separation the proteins were transferred onto a 
PVDF membrane (at 400 milliamps for 1 hour). This was followed by blocking with 5% 
milk in Tris-buffered saline-tween 20 (TBST) for one hour and probing with the relevant 
primary antibody overnight.  Following 2 thirty minute washes with TBST, a horse 
radish peroxidase (HRP) conjugated secondary antibody was added for 1 hour and the 
protein band was observed following addition of Super signal West Pico 
chemiluminescent substrate (Thermo Scientific).  The following antibodies were used: 
HdmX /Mdm4 A300-287A (Bethyl labs), actin AC-40 (Sigma), p53 FL393 (Santa Cruz 
Technology), anti-rabbit IgG HRP (Promega), anti-mouse IgG HRP (Promega).   
Relative quantification of western blots was performed with ImageJ.  Values shown are 
relative to the control condition and normalized to actin, to control for any protein 
loading inequalities. 
Cloning 
For the plasmid “psicheck2 Exon 11”, a 444 bp region of the coding region of exon 11 of 
the human MDM4 gene, surrounding the putative ORF miR-34a site, was amplified by 
PCR from BAC 433N15 (BACPAC Resources Center) and inserted between SgfI and NotI 
sites in the psicheck2 reporter plasmid (Promega) downstream of renilla luciferase.  
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Cloning primers were: sense 5‟- AAA AAA GCG CCT TGA GGA AGG ATT GGT AT -3‟ and 
antisense 5‟- AAA AAA GCG GCC GCA GCC CCA GCC TTC TTT AGT C -3‟.  
PCR was set up as follows: SYBR green PCR master mix=25 µl, BAC template=1 µl, 
cloning primers= 2 µl each, water=20 µl, total volume=50 µl. PCR conditions :95oC=10 
minutes, 40 cycles of 95oC=30 seconds, 55oC=40 seconds and 72oC=25 seconds, 72oC=5 
minutes and hold at 4oC). Following PCR the digestion of insert and vector was 
performed. 
 Insert digest 
(µl) 
Vector digest 
(µl) 
Final 
Concentrations 
AsisI  2 2 2 units/µl 
NotI 1 1 1 unit/µl 
NEB4 buffer 1 1 1X 
BSA  1 1 1X 
Shrimp alkaline phosphatase 
(SAP) 
- 1 1 unit/µl 
Insert (PCR product) 6  - 
Psicheck2 - 5 - 
Total 10 10 - 
The digest mixtures were incubated at 37oC for 90 minutes followed by incubation at 
80oC for 20 minutes.  
The next step in the protocol was to ligate the digested insert and vector. The ligation 
reaction mixture included: T4 ligase=1 µl, T4 ligase buffer=2 µl, insert and vector in the 
ratio 3:1, final volume made upto 10µl with water. The reaction mixture was incubated at 
25oc for 10 minutes followed by overnight incubation at 16oC. 
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This ligation mixture was used to transform 50 µl of TOP10 cells. One vial of TOP10 cells 
corresponding to 50 µl volume was thawed on ice for 30 minutes. To this was added 5 µl 
of the ligated product (no mixing of the contents). The contents were incubated on ice for 
30 minutes followed by 30 seconds incubation at 42oC. The reaction mixture was placed 
on ice briefly after which was added 250 µl of SOC media. This mixture was incubated 
horizontally in a shaker incubator at 37oC set at 225RPM for 60 minutes. Fifty µl of the 
reaction mixture was plated on LB+Amp plates followed by overnight incubation at 370C. 
Colonies are picked randomly and inoculated in LB+Amp liquid media and again 
incubated overnight at 37oC. Following growth in the liquid media these are processed 
for plasmid extraction. 
Plasmid DNA purification. 
The plasmid DNA was extracted using the Hurricane miniprep protocol (Gerard 
Biotech). The bacterial culture was transferred to a 1.5ml centrifuge tube and centrifuged 
at 10,000g for 1 minute. The bacterial pellet was resuspended in 250 µl of Buffer A by 
pipetting. This was followed by addition of 250 µl of Buffer B and mixed thoroughly by 
inverting the tubes 10 times and lastly was added 325 µl of Buffer C and mixed gently by 
inverting 10 times. The mixture was centrifuged at 10,000g for 10 minutes. The 
supernatant was transferred to a DNA binding column and centrifuged at 10,000g for 1 
minute. The liquid from the tube was discarded and to the DNA binding column was 
added 750 µl of 70% ethanol and centrifuged at 10,000g for 1 minute. The ethanol was 
discarded and the tubes were centrifuged for an additional 3 minutes to remove excess 
ethanol. The DNA binding column was then placed in 1.5 ml collection tubes to these was 
added 50 µl of preheated (65oC-70oC) sterile water and centrifuged at 10,000g for 1 
minute after allowing standing at room temperature for 1 minute. Identity of all clones 
was verified by sequencing (Retrogen).   
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Ethanol precipitation to purify DNA from the PCR product. 
The purification of the PCR product began with addition of 1/10th volume of sodium 
acetate (3M pH=5.2) followed by addition of 2 volumes of cold (-20oC) 100% ethanol and 
proper mixing of the contents. The contents were then incubated at -20oC for 20 minutes 
and spun at maximum speed for 10 minutes at 40C. The supernatant was decanted 
followed by addition of 1ml of cold (-200C) 70% ethanol and again spun at maximum 
speed for 5 minutes at 40C. The supernatant was decanted and pipetted out. The pellet 
was subjected to speed vac but no heat to dry. The dry pellet was suspended in 12 µl of 
water. 
Site Directed Mutagenesis. 
The plasmid “psicheck2 exon 11 A>C” was generated by site-directed mutagenesis of the 
“psicheck2 exon 11” plasmid according to the QuikChange II Site-Directed Mutagenesis 
kit and protocol (Aligent Technologies).  An A to C mutation was generated to 
correspond to the human SNP rs79824231, which lies in the seed region of the exon 11 
ORF miR-34a site.  Mutagenic primers were: sense 5‟- CTC TCC ACG TCT GAT ATC CCT 
GCC AT ACCT GAA AA -3‟ and antisense 5‟- TTT TCA GGT ATG GCA GGG ATA TCA 
GAC GTG GAG AG -3‟.  Mutation of the target site was verified by sequencing.   
Sequence alignment 
Sequences were retrieved from GenBank and aligned using ClustalW2 v2.1 with default 
(slow) alignment settings.  The accession and version numbers for sequences used were: 
Mus musculus EU568360.1, Rattus norvegicus NM_001012026.1, Xenopus laevis 
NM_001088965.1, Pan troglodytes XM_003308706.1, human MDM4 NM_002393, 
and human MDM2 NM_002392.3.   
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III. RESULTS 
 
Previous work/Background 
Initially it was thought that MdmX was constitutively transcribed and it is controlled at 
the level of translation where the expression of MdmX protein is affected probably 
through ubiqutin mediated proteasomal degradation catalysed by Mdm2. The same was 
believed to happen with respect to control of the human MDMX (HDMX or MDM4) 
expression. However previous work in the laboratory showed that the levels of full length 
MDM4 decreased in response to genotoxic stress. It was seen that the decrease in hdmx 
transcript levels was species specific as it was not observed in murine cell lines and 
independent of the p53 status, type of cell line and type of DNA damage (Figure 5). 
 
It was also shown that apart from the established ubiqutin mediated proteasomal 
degradation, the decrease in full length transcripts following genotoxic stress also 
contributed to decrease in levels of MDM4 proteins. In order to ascertain the cause for 
the reduction in full length transcripts certain potential factors were explored. Firstly, 
change in the promoter activity as a potential cause for reduction in full length 
transcripts was explored.  HCT116 (wt p53), HCT116 (p53-/-), MCF7 and H1299 were 
transcfected with MDM4 promoter –luciferase gene construct or constitutive CMV-
luciferase gene construct as a control. Reporter assays were performed to assess 
expression of the promoter construct. There was no significant change in promoter 
activity following DNA damage which could account for this decrease (Figure 6). 
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Figure 5: hdmX (MDM4) is transcriptionally repressed in response to DNA 
damage independent of p53 status, and in non-tumor human fibroblasts.  
Markey M, Berberich SJ (2008) Full length MDM4 transcripts decrease 
following genotoxic stress. Oncogene 27: 6657-6666. 
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Figure 6: The activity of an MDM4 promoter-luciferase gene construct is 
unchanged by exposure to doxorubicin. The activity of the MDM4 promoter was 
unchanged similar to that observed with a constitutive CMV promoter-
luciferase gene construct. 
Markey M, Berberich SJ (2008) Full length hdmX transcripts decrease 
following genotoxic stress. Oncogene 27: 6657-6666. 
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It was earlier seen that in response to DNA damage alternative splice variants of MDM4 
were produced (Chandler 2006). Hence, production of alternative splice variants of 
MDM4 in response to DNA damage conditions as a possible mechanism leading to 
reduction of full length transcripts was studied. A loss of full-length MDM4 mRNA levels 
in several cell lines and concurrent induction of XALT2 mRNA was observed. Alternative 
splicing could not be the only mechanism leading to the loss of MDM4 transcripts based 
on two findings in this report. Based on the experiments where absolute quantification of 
XALT2 transcripts and full length transcripts indicated that the observed decrease in full 
length transcripts was not fully compensated by the increased levels of XALT2 variant 
transcripts (Figure 7B). Experiments showed that alternative splice variants could not 
fully explain this observed effect on full length transcripts in response to DNA damage 
(Figure 7). 
In addition to this there was evidence of destabilization of MDM4 mRNA as seen by 
decreased half-life of full-length MDM4 mRNA following DNA damage. 
Towards understanding the basis for the MDM4 mRNA degradation, there were several 
reports demonstrating that miR-34a could be induced upon DNA damage and MDM4 
was one of the mRNAs downregulated by miR-34a overexpression (Chang 2007). In this 
direction the work of the laboratory showed presence of several potential miR-34a 
binding sites in the 3‟UTR of the MDM4 transcript.  Some data from the laboratory 
showed a correlation between miR-34a and reduction of MDM4 transcripts. It was also 
seen that with the use of anti-miR- 34a to reduce miR-34a there was an increase in full-
length MDM4 mRNA (Figure 8). The role of miR34a as the sole factor responsible for 
reduction of MDM4 levels could not be established. However, these results suggest 
micro-RNA expression may play an important role in the regulation of MDM4mRNA 
expression and thereby impact p53 activity (Markey 2008). 
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Figure 7: A) Alternative transcripts of hdmX are differentially regulated in 
response to increasing doses of the DNA-damaging agent cisplatin B) Absolute 
Q–PCR analysis of full-length hdmX and XAlt2 transcripts 
Markey M, Berberich SJ (2008) Full length hdmX transcripts decrease 
following genotoxic stress. Oncogene 27: 6657-6666. 
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It was previously shown that overexpression of miR-34a led to decrease in expression of 
a large number of mRNAs and HDMX/MDM4 was one among them (Chang 2007). 
Consistent with this report the 3‟UTR of MDM4 was found to possess several potential 
miR-34a binding sites (Markey 2008). It was also shown that when MCF7 cells were 
transfected with anti-34a (inhibitor for miR-34a) and non-targeting control in presence 
and absence of doxorubicin treatment, significant increase in MDM4 expression was 
observed with inhibition of miR-34a in absence of doxorubicin. However in presence of 
doxorubicin efficient reduction of miR-34a could not be achieved. Hence the role of miR-
34a as a sole factor responsible for reduction of MDM4 could not be ascertained. 
However miR-34a was found to have a potential role in this phenomenon (Figure 8) 
(Markey 2008). 
Studies have shown that miR-34a is frequently silenced or downregulated in various 
types of cancer as it is located on a region on the 1p chromosome which is frequently lost 
in certain types of cancers (He 2011). Also MDM4 is shown to be overexpressed in 
certain cancers (Danovi 2004). Hence the next set of experiments sought to determine 
the relationship between miR-34a expression and MDM4 expression, their expression 
was analysed in a variety of cell lines of different origins and p53 status. H1299 (non-
small cell lung carcinoma, p53 null) and SAOS2 (osteosarcoma, p53 null) expressed low 
levels of miR-34a. MCF7 (breast carcinoma, p53 wild type), U2OS (osteosarcoma, p53 
wild type) and IMR90 (primary human fibroblasts) all expressed high basal levels of 
miR-34a which were further induced upon doxorubicin treatment only in MCF7. Hence 
in absence of DNA damage conditions the expression of miR-34a was consistent with 
p53 mediated transcription of miR-34a (Hermeking 2011). All cell lines except SAOS2 
showed downregulation of MDM4 following doxorubicin treatment (Figure 9).  
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Figure 8: Effect of inhibition of miR-34a in presence and absence of 
doxorubicin treatment. MCF7 cells were transfected with the indicated 
antimicroRNA (Neg, negative control anti-miR; mi-34a, miR-34a) prior to DNA 
damage with 0.5mg/ml doxorubicin (+dox).  
Markey M, Berberich SJ (2008) Full length hdmX transcripts decrease 
following genotoxic stress. Oncogene 27: 6657-6666.                        
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Figure 9:  Expression of miR-34a and MDM4 in cell lines of different 
origin and p53 status. qRT-PCR analysis of miR34a and MDM4 expression. 
Error bars show 95% confidence intervals. Double asterisks indicate paired, 
one-tailed t-test values, <0.01 comparing the untreated to doxorubicin treated 
condition for each cell line. 
Mandke et al (2012) MicroRNA-34a Modulates MDM4 Expression via a Target 
Site in the Open Reading Frame, PLoS One, 7. 
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The previous experiment showed that there is an inverse relationship between miR-34a 
expression and MDM4 expression in some of the cell lines viz H1299 and MCF7. In the 
cell line SAOS2 it was observed that even with an induction of miR-34a after doxorubicin 
treatment an increase in MDM4 expression was observed. Hence an absolute 
relationship between expression of miR-34a and MDM4 could not be established. 
 
However to verify the observations in H1299 and MCF7 cell line we sought to determine 
the effect of overexpression and inhibition of miR-34a on MDM4 expression in 
comparison to the effect of miR-34a on two of its known targets. Cell cycle associated 
genes CDK6 and CCND1 were selected as known targets of miR-34a as it has been 
demonstrated with previous work that ectopic overexpression of miR-34a leads to 
reduction in mRNA and protein levels of CDK6 and CCND1 (Sun 2008). 
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Effect of overexpression of miR-34a on expression of MDM4 and known 
miR-34a targets CDK6 and CCND1. 
MCF7 cells were transfected with miR-34a overexpression plasmid and a miR-34a mut 
plasmid as a control (this plasmid does not produce mature miR-34a). Following 24 
hours of transfection cells were subjected to GFP expression analysis to determine 
transfection efficiency. This was followed with RNA isolation and qRT-PCR analysis for 
the expression of MDM4, CDK6 and CCND1. It was seen that in comparison with the 
miR-34a mut control the expression of MDM4 in response to miR-34a was reduced. A 
reduction in expression was also observed in case of the known targets CDK6 and 
CCND1 (Figure 10A). Having ascertained the effect of miR-34a overexpression on mRNA 
levels of MDM4 this was followed up with ascertaining effect of overexpression of miR-
34a on protein levels of MDM4. MCF7 cells were transfected with miR-34a 
overexpression plasmid and a miR-34a mut plasmid as a control. Following 48 hours of 
transfection cells were subjected to protein extraction and western blot analysis using 
antibodies for MDM4, p53 and actin. As seen with the mRNA levels of MDM4 in 
comparison to the miR-34a mut MDM4 protein levels were seen to decrease in response 
to miR-34a overexpression (Figure 10B). 
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A) 
 
 
 
 
 
 
 
 
  
B) 
 
 
 
 
  
 
 
Figure 10: A) Effect of overexpression of miR-34a on mRNA levels of 
MDM4 and known targets of miR-34a viz. CDK6 and CCND1. B) 
Effect of overexpression on protein levels of MDM4. Asterisks and 
double asterisks indicate t-test values <0.05 and <0.01, respectively, comparing 
the miR-34a expression plasmid to the control mutant. 
Mandke et al MicroRNA-34a Modulates MDM4 Expression via a Target Site in 
the Open Reading Frame, PLoS One, 7 
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Effect of inhibition of endogenous miR-34a on expression of MDM4 and 
known miR-34a targets CDK6 and CCND1. 
To verify this effect of overexpression of miR-34a on MDM4, CDK6 and CCND1 
expression we sought to see if inhibition of endogenous miR-34a levels in MCF7 could 
alleviate the repression imposed by miR-34a on these genes. MCF7 cells were selected as 
they express high levels of endogenous miR-34a and MDM4. MCF7 cells were 
transfected with anti-miR-34a. Following 24 hours of transfection cells were subjected to 
RNA isolation and qRT-PCR analysis for the expression of MDM4, CDK6 and CCND1. In 
comparison to the untransfected control there was an increase in expression of MDM4 in 
response to inhibition of endogenous miR-34a. An increase in expression of CDK6 and 
CCND1 was also observed (Figure 11A). 
MCF7 cells were transfected with anti-miR-34a. Following 48 hours of transfection cells 
were subjected to protein extraction and western blot analysis. Untransfected MCF7 cells 
served as control. In comparison to untransfected control it was seen that inhibition of 
endogenous miR-34a also led to increase in the protein levels of MDM4 (Figure 11B). 
 
As mentioned before, microRNAs affect expression of their target genes by binding via 
their seed sequences to complimentary or near complimentary sites in the 3‟UTR. Hence 
a 1700bp region of the 3‟UTR of MDM4 expected to contain miR-34a binding sites was 
cloned into the psicheck2 (Promega) vector upstream of the renilla luciferase between 
the sgf1 and not1 restriction endonuclease sites (Figure 12). 
 
These plasmids were used for reporter assays to check for responsiveness of the 3‟UTR to 
overexpression of miR-34a. 
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Figure 11: Analysis of MDM4, CDK6 and CCND1 after transfection 
with anti-miR-34a.  A) MCF7 cells were transfected with inhibitor to miR-
34a (anti-miR-34a) at 80% confluence. Untransfected MCF7 cells served as 
control. 24 hours post transfection cells were subjected to RNA extraction by 
TRIZOL followed by RNA extraction. MDM4, CDK6 and CCND1 levels were 
analysed using qRT-PCR and normalized to GAPDH. Error bars represent the 
95% confidence intervals resulting from quadruplicate assays for both miR-34a 
and miR213 expression. Asterisks and double asterisks indicate t-test values 
<0.05 and <0.01, respectively, comparing the anti-miR34a to the untreated 
controls. 
 
B) MCF7 cells were transfected with inhibitor to miR-34a (anti-miR-34a) at 
80% confluence. Untransfected MCF7 cells served as control. 48 hours post 
transfection cells were subjected to protein extraction and western blot analysis 
using antibodies for MDM4, p53 and actin. 
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Figure 12: Schematic of the psicheck2 vector with 1700bp region of the 
3’ untranslated region (UTR) cloned between the NotI and SgfI sites. 
The psicheck 2 plasmid is routinely used for RNA interference studies. The 
plasmid has the genes for both the reporters: hRluc (Renilla luciferase 
experimental reporter) and hluc (Firefly luciferase control reporter). The 
plasmid also possesses an ampicillin resistance marker. 
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Overexpression of miR-34a in both MCF7 and H1299 cell lines was confirmed. Both the 
cell lines were transfected with miR-34a or miR-34a mut. 24 hours post transfection 
cells were subjected to RNA extraction followed by microRNA extraction. The expression 
of miR34a was quantitated by qRT-PCR. As compared to miR-34amut we could achieve 
high levels of expression of miR-34a in both the cell lines. The increase in H1299 which 
expresses low levels of endogenous miR-34a levels was 250 fold as compared to a 50 fold 
increase in MCF7 cells which already express high levels of endogenous miR-34a (Figure 
13A and 13B). 
 
With both the cell lines being able to express increased levels of miR-34a after 
transfection of miR-34a overexpression plasmid, these were transfected with psicheck2 
containing the 1700 bp region of the 3‟UTR of MDM4 (psicheck2-MDM4) and 
cotransfected with miR-34a and miR-34amut. As a control, cells were transfected with 
empty psicheck2 plasmid and cotransfected with miR-34a and miR-34amut. 24 hours 
post transfection the cells were processed for obtaining cell lysates and the reporter assay 
was performed. It was observed that the response of the psicheck2-MDM4 reporter was 
identical to the response of empty psicheck 2 to both the miR-34a and miR-34a mut. 
Indicating that though predicted to contain miR-34a binding sites the 3‟UTR of MDM4 
was unresponsive to miR-34a mediated repression (Figure 14A and 14B). 
41 
 
A) 
 
 
 
 
 
 
 
 
 
  
B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MCF7
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
miR-34a-mu  miR-34a
transfection
R
e
la
ti
v
e
 R
Q
miR-34a
H1299
0
50
100
150
200
250
300
350
miR-34a-mut miR-34a
R
Q miR-34a
MCF7 
 
miR-34a miR-34a-mut 
** 
H1299 
 
miR- 4a miR- a-mut 
*** 
miR-34a 
R
e
la
ti
v
e
 e
x
p
r
e
s
s
io
n
 
R
e
la
ti
v
e
 e
x
p
r
e
s
s
io
n
 
42 
 
Figure 13: qRT-PCR analysis of miR-34a after transfection with miR-
34a overexpression plasmid. A) qRT-PCR of miR-34a overexpression in 
MCF7 cells. Mandke et al (2012) MicroRNA-34a Modulates MDM4 Expression 
via a Target Site in the Open Reading Frame, PLoS One, 7 
 
B) H1299 cells were transfected with miR-34a overexpression plasmid at 80% 
confluence. H1299 cells transfected with miR-34a mut  served as control. 24 
hours post transfection cells were subjected to RNA extraction by TRIZOL 
followed by microRNA extraction. miR-34a levels were analysed using qRT-
PCR and normalized to miR-213 levels. Error bars represent the 95% confidence 
intervals resulting from quadruplicate assays for both miR-34a and miR213 
expression.  
Double and triple asterisks indicate paired, one-tailed t-test values <0.01 and 
<0.001 respectively between control and experimental conditions. 
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A) 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
  
 
 
Figure 14: Effect of miR-34a overexpression on psicheck2-MDM4 
(1700 bp 3’UTR reporter of MDM4) in A) MCF7 cells B) H1299 cells 
Mandke et al MicroRNA-34a Modulates MDM4 Expression via a Target Site in 
the Open Reading Frame, PLoS One, 7 
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Hence the 3‟UTR region with potential miR-34a binding sites was not responding to 
miR-34a mediated downregulation.  
 
Reassessment of the MDM4 was performed using the August 2010 release of the 
miRANDA software an improved version of the miRanda software. This model predicts 
microRNA target mRNAs based on the likelihood of downregulation by providing a 
mirSVR score. The model is based on information extracted from miRANDA predicted 
target sites. The use of this model enables prediction of several noncanonical or non-
conserved microRNA target sites. The mirSVR score is interpreted as more negative the 
value better is the downregulation indicating a strong regulatory site. 
 This software did not identify any of the previous sites identified to be potential miR-
34a binding sites in the 3‟UTR however a strong candidate site was identified in the 
protein coding exon 11 of the MDM4 gene (Figure 15). As seen from the schematic 
the model predicts several miR-34a sites in the 3‟UTR however these have a score >-0.05 
indicating poor regulatory sites. However the site in the exon 11 coding region has a 
mirSVR score of -1.286 making this a potential strong miR-34a regulatory site 
(microRNA.org August 2010 release). 
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Figure 15: schematic of the exon 11 coding region and 3’UTR of the 
MDM4 gene with probable miR-34a regulatory sites (inverted 
triangles). Values indicate the mirSVR score of the respective sites. 
(microRNA.org August 2010 release) 
(Schematic not to scale) 
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Cloning of the miR-34a site in the exon 11 in the psicheck 2 vector 
To determine if the new miR-34a binding site predicted in the exon 11 of MDM4 is a 
functional site, a reporter was constructed with this region cloned downstream of a 
luciferase gene in a vector called the psicheck2 vector.  
BAC 433N15 was used as template to PCR amplify the predicted site To begin with 
Platinum Taq DNA polymerase was used to amplify the region expected to be 
approximately 120bp region in length. However a 1% agarose gel analysis did not reveal 
the presence of any amplified product. Indicating this PCR had not worked. Hence 
another PCR was set up using RT2 SYBr green PCR master mix with BAC DNA as 
template and the specific primers. On a 1% agarose gel a product was obtained 
approximately of the size corresponding to the size of expected region.. Hence RT2 SYBR 
green PCR master mix was used for the consequent experiments. 
 
Since this could be the region of interest a digestion reaction of the insert region in the 
PCR product and the psicheck2 vector with NotI and SgfI restriction endonucleases was 
set up, followed by ligation and transformation of bacterial cells. After overnight 
incubation at 370C no colonies were obtained on LB+Amp plates.  
We tried to address the problem by verifying the digestion of the insert, purifying the 
insert PCR product by ethanol precipitation and the ligation of insert to the vector. 
However we were unable to get clones of bacterial cells harboring the plasmid with the 
120bp region. One of the possible difficulties was the inability to probably get a pure 
120bp product. This could have resulted in the problem associated with the ligation of 
the insert to the vector. 
 
Having tried to address the cloning of this 120bp region we decided to use primers for a 
longer region of the exon 11 of MDM4 still containing the potential miR-34a binding site. 
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The new primers would give a product approximately 444bp long. For this purpose we 
again used BAC DNA as template DNA, primers for 444bp region and RT2 SYBr green 
PCR master mix and same PCR conditions as before, ethanol precipitation to purify the 
product, followed by digestion of amplified insert and vector by NotI and SgfI, ligation 
and transformation. On obtaining colonies on the LB+Amp plate after 24 hours 
incubation at 370C; 6 single colonies were randomly selected and inoculated in LB+Amp 
broth and incubated overnight on a shaker incubator at 370C. The liquid culture if turned 
was processed for plasmid extraction. 2 colonies grew in the overnight culture.  
 
One of the methods to test the presence of the region of interest in the psicheck2 vector 
was digestion with restriction endonuclease EcoRI. The plasmid map indicates the 
presence of two EcoRI sites (Figure 16A). One between the two restriction sites NotI and 
SgfI and the other after NotI site. Hence digestion of psicheck 2 + insert upon with 
EcoRI should give a single product (~6500bp) corresponding to digestion of the site 
after NotI and inactivation of the site between NotI and SgfI due to presence of the 
insert. In case of absence of the insert the digestion would yield two products (732bp and 
5541bp).  
 
The plasmid extracted from these two colonies was digested with EcoRI (370C for 60 
minutes). The bands observed after separation on a 1% agarose gel did not reveal the 
expected pattern (Figure 16B). In case of the psicheck2+insert plasmid digestion with 
EcoRI gave a single product as expected but of a comparatively smaller size than 
expected. In case of the empty vector the digestion yielded a larger product of ~4000bp 
(smaller than the expected 5541 bp) and a smaller product corresponding to 732bp was 
not observed. Hence, due to the absence of a smaller product we could not conclusively 
ascertain the presence of insert in the psicheck2+insert plasmid.
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A) 
 
B) 
 
 
 
Figure 16: Elucidating presence of the insert by EcoRI mediated 
restriction digestion. A) Schematic of psicheck 2 vector with 2 EcoRI and 
single NotI and AsisI (SgfI) site. 
 
B) Empty psicheck2 vector and 2 plasmids suspected to contain the insert were 
digested with EcoRI (incubation at 37C for 60 mins). The products after 
digestion were analysed on a 1% agarose gel. 
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Since the pattern of digestion of the empty psicheck2 with EcoRI did not match the 
expected sizes, we sought to determine the quality of the psicheck2 vector by subjecting 
it to digestion by 6 endonucleases (BamHI, EcoRI, NotI, NcoI, SgfI and XhoI). Psicheck2 
plasmid was incubated with the mentioned endonucleases for 60 minutes at 370C. The 
final product was run on a 1.2% agarose gel. The expected product sizes were (BamHI= 
6273bp, EcoRI=5541bp and 732bp, NcoI=3758bp, 1375bp and 463bp, NotI, SgfI, 
XhoI=6273bp,). We did obtain the products of expected sizes for all the restriction 
endonucleases except for SgfI (Figure 17). Hence from the pattern of fragments obtained 
from the restriction digestion it could be said that the psicheck2 vector itself was suitable 
for use. However since SgfI is one of the restriction sites used to clone the region of 
interest in the psicheck 2 and the digestion mediated by it did not match the expected 
fragment size the digestion with SgfI had to be addressed. 
 
To address this problem, psicheck2 digestions with new AsisI were set up with different 
quantities of the enzyme itself (1µl and 2µl) and NEB3 and NEB4 buffer. The enzyme is 
known to have 100% activity with the use of both NEB3 and NEB4 buffers however the 
suitability of each had to be determined for our experimental conditions. Amongst this 
the combination of 2ul enzyme with NEBB4 gave the expected result of a single product 
indicating efficient digestion instead of a smear or range of products as seen with the 
other combinations. This combination was used for the further experiment (Figure 18). 
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Figure 17: Restriction digestion of Psicheck 2 vector. The psicheck2 
vector was digested with 6 restriction endonucleases BamHI, EcoRI, NcoI, NotI, 
XhoI and SgfI (incubation at 370C for 60 minutes). The products obtained after 
digestion were analysed on a 1.2% agarose gel. The sizes of the fragments 
obtained were compared with documented sizes.  
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Figure 18: Restriction digestion of psicheck 2 with restriction 
endonuclease SgfI. Psicheck2 was digested with different combinations of 
amount of SgfI and NEB4 buffers. The combinations considered were 1µl and 
2µl of SgfI with NEB3 buffer and 1µl and 2µl of SgfI with NEB4 buffer 
(incubated at 370C for 60 minutes). The products after digestion were analysed 
on 1% agarose gel. 
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We went back to the BAC 14532 and PCR amplified the 444bp region using the new 
primers, digestion of the amplified insert region and vector was carried out using 
modified conditions (2µl of  SgfI and NEB4 buffer), followed by ligation and 
transformation of bacterial cells. Several colonies were obtained on the LB+Amp plate 
after overnight incubation at 370C. Out of 6 random colonies inoculated in LB+Amp 
broth one could be processed further for plasmid extraction.  This plasmid was further 
set up for EcoRI digestion to verify the presence of insert along with digestion of 
psicheck2 as control. Following EcoRI digestion; psicheck 2 and psicheck2+insert gave a 
larger product corresponding to ~6000bp. However, the smaller product (732bp) 
expected to see with the digestion of psicheck2 was not observed (Figure 19). 
Since EcoRI digestion was inconclusive we sought to verify the presence of the insert by 
PCR amplification of the insert from the psicheck2+insert using the same primers used 
to amplify the insert sequence from the BAC. HCT116 was used as a positive control, 
psicheck2 (negative control) and psicheck2 + insert was the test. Both for the test and 
HCT116 a ~450 bp product was observed on a 1.4%agarose gel which was absent in the 
empty psicheck2. Hence it could be said the psicheck2+ insert could potentially have the 
region of interest (Figure 20A). 
This plasmid was further sent for sequencing to verify the presence of the insert. 
The results of the sequencing revealed the successful cloning of the ~444bp region of the 
exon 11 into the psicheck2 reporter (henceforth referred to as Exon11) (Figure 20B). 
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Figure 19: EcoRI digestion of plasmids from one clone to ascertain 
presence of 444bp insert. Empty psicheck 2 vector and psicheck2+ 444bp 
insert suspected to contain insert was digested with EcoRI (incubation at 370C 
for 60 minutes). The products after digestion were observed on a 1.2% agarose 
gel. 
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A) 
 
B) 
 
 
Figure 20: PCR to verify presence of 444bp insert in one of the 
engineered psicheck2 vectors. A) PCR was set up using water (negative 
control), cDNA from HCT116 (positive control) and plasmid suspected to 
contain the 444bp insert. Primers specific for 444bp region and RT2 SYBr green 
PCR master mix was used to perform the PCR. B) Schematic of the psicheck2 
with the 444bp region of interest between the NotI and SgfI restriction sites. 
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Reporter assays 
The successful cloning of the miR-34a site from the exon 11 of MDM4 in the psicheck2 
vector was followed by reporter assays to test the functionality of the miR-34a site. 
 
Effect of inhibition of endogenous miR-34a on exon11 reporter activity: 
Firstly we sought to determine the effect of inhibition of endogenous miR-34a on the 
reporter activity. If the miR-34a site found to be strong candidate site for regulation was 
indeed a functional site then inhibition of endogenous miR-34a by the anti-miR-34a 
would be able to relieve the repression imposed by presence of miR-34a. MiR-34a is 
expected to bind this site in the exon11 and bring about downregulation of MDM4 
expression. 
 
For this the MCF7 cell line was selected as it possesses high level of endogenous miR-34a 
and MDM4 expression. The expression of endogenous miR-34a was knocked down with 
the use of an antisense oligonucleotide (Ambion) an inhibitor of miR-34a. 
 
To verify the inhibition of endogenous miR-34a MCF7 cells were transfected with anti-
miR-34a. Untransfected cells served as a control. 24 hours after transfection MCF7 cells 
were subjected to microRNA extraction, reverse transcription to get cDNA and qRT-PCR 
analysis to check for miR-34a expression (Figure 21). 
 
Transfection with the inhibitor was able to bring about a 80% reduction in endogenous 
mir-34a expression as compared to the untransfected control. This validated the use of 
the inhibitor for the reporter assays.  
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Figure 21:  qRT-PCR analysis of miR-34a after transfection with anti-
miR-34a. MCF7 cells were transfected with inhibitor to miR-34a (anti-miR-
34a) at 80% confluence. Untransfected MCF7 cells served as control. 24 hours 
post transfection cells were subjected to RNA extraction by TRIZOL followed by 
microRNA extraction. miR-34a levels were analysed using qRT-PCR and 
normalized to miR-213 levels. Error bars represent the 95% confidence intervals 
resulting from quadruplicate assays for both miR-34a and miR213 expression. 
Double asterisks indicate t-test values <0.01, comparing the anti-miR-34a to 
the untreated control. 
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For this MCF7 cells were transfected with anti-miR-34a and co transfected with either 
empty psicheck2 vector or exon11 plasmid. The control cells were transfected with just 
the empty psicheck2 or exon11 plasmid. The plasmid psicheck2-AS34a contains a 
consensus response site for miR-34a, and was used as a positive control for response to 
miR-34a inhibition. 24 hours post transfection cell were processed for obtaining the 
lysates. These lysates were used for performing the Dual luciferase reporter assay 
(Promega). 
It was observed in response to inhibition of endogenous miR-34a the activity of the 
exon11 reporter was found to increase in comparison with the empty vector under the 
same conditions and also when compared to the untransfected controls. The increase 
was also comparable to increase observed for the reporter with the consensus miR-34a 
response site (Figure 22 A, B). 
 
Effect of overexpression of miR-34a on exon11 reporter activity. 
Next we sought to determine the effect of overexpression miR-34a on the reporter 
activity. If the miR-34a site in the exon11 of MDM4 found to be strong candidate site for 
regulation was indeed a functional site then overexpression of miR-34a using miR-34a 
overexpression plasmids should be able to repress the expression of the reporter. MiR-
34a is expected to bind this site in the exon11 and bring about downregulation of MDM4 
expression. 
 
For this the H1299 cell line was selected as it expresses low levels of endogenous mir-34a 
and MDM4. The overexpression of miR-34a was achieved by using miR-34a 
overexpression plasmids. 
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A) 
 
 
 
 
 
  
B) 
 
 
Figure 22: Effect of inhibition of endogenous miR-34a on expression 
of exon11 reporter. A) MCF7 cells were transfected with anti-miR-34a and 
cotransfected with either empty psicheck2 or exon11. Control cells were 
transfected with empty psicheck2 or exon11. 24 hours post transfection cells 
were processed for obtaining lysates and relative luciferase activity was 
measured. Error bars represent results from six independent experiments.  
B) Similar experiment was performed using plasmid containing a control site 
for miR-34a known to respond to miR-34a. Asterisks and triple asterisk 
indicate t-test values <0.05 and <0.001 respectively. 
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To verify the overexpression of miR-34a H1299 cells were transfected with miR-34a 
overexpression plasmids. H1299 cells transfected with miR-34amut served as the 
control. 24 hours after transfection H1299 cells were subjected to microRNA extraction, 
reverse transcription to get cDNA and qRT-PCR analysis to check for miR-34a 
expression (Figure 23). 
 
Transfection with the overexpression plasmid was able to bring about a 250 fold increase 
in endogenous mir-34a expression as compared to the H1299 cells transfected with miR-
34amut plasmid.  This indicated robust induction of miR-34a expression inH1299 cells 
validating the use of this system for the reporter assay. 
 
For this H1299 cells were transfected with miR-34a and cotransfected with empty 
psicheck2 vector or exon11. The control cells were transfected with miR-34a mut  and 
cotransfected with psicheck2 or exon11 plasmid. The plasmid psicheck2-AS34a contains 
a consensus response site for miR-34a, and was used as a positive control for response to 
miR-34a overexpression.24 hours post transfection cell were processed for obtaining the 
lysates. These lysates were used for performing the reporter assay. 
It was observed in response to overexpression of miR-34a the activity of the exon11 
reporter was found to decrease  in comparison with the empty vector under the same 
conditions and also when compared to the H1299 cells transfected with miR-34amut. 
The decrease was also comparable to decrease observed for the reporter with the 
consensus miR-34a response site (Figure 24 A, B). 
 
From both the experiments it was seen that the reporter with the new miR-34a site from 
the exon11 was responding to manipulation of endogenous miR-34a in the different cell 
lines; indicating it is indeed a functional regulatory site. 
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Figure 23: qRT-PCR analysis of miR-34a after transfection with miR-
34a overexpression plasmid. H1299 cells were transfected with miR-34a 
overexpression plasmid at 80% confluence. H1299 cells transfected with miR-
34amut  served as control. 24 hours post transfection cells were subjected to 
RNA extraction by TRIZOL followed by microRNA extraction. miR-34a levels 
were analysed using qRT-PCR and normalized to miR-213 levels. Error bars 
represent the 95% confidence intervals resulting from quadruplicate assays for 
both miR-34a and miR213 expression. Triple asterisks indicate p-value <0.001. 
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Figure 24: Effect of overexpression miR-34a on expression of exon11 
reporter. A) H1299 cells were transfected with miR-34a and cotransfected 
with either empty psicheck2 or exon11. Control cells were transfected with miR-
34amut and cotransfected with empty psicheck2 or exon11. 24 hours post 
transfection cells were processed for obtaining lysates and relative luciferase 
activity was measured. Error bars represent results from six independent 
experiments.  Double asterix indicate p value <0.01. 
 
B) Similar experiment was performed using plasmid containing a control site 
for miR-34a known to respond to miR-34a regulation. 
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Site directed Mutagenesis to create point mutants corresponding to the SNP 
found in the miR-34a site in exon 11. 
 
It was shown that the miR-34a seed region in the exon11 is also a site for a human single 
nucleotide polymorphism (SNP) (The 1000 Genome Project Consortium 2010). This 
SNP is an A to C transversion, the presence of which we predict would render this miR-
34a site unresponsive to miR-34a mediated regulation (Figure 25A) is found at the 
frequency of 21.6% in the global population. Against this background all our cell lines 
were assessed for the presence of this SNP. However none of the cells were seen to 
possess this C allele instead they had the A allele.  
However we set out to ascertain the effect of this SNP on miR-34a mediated regulation of 
MDM4. Point mutations corresponding to the A to C transversion were created by site 
directed mutagenesis using specific primers. 4 colonies from the colonies obtained on 
LB+ Amp after overnight incubation at 370C were inoculated in LB+Amp broth. After 
overnight incubation at 370C on a shaker, the broth was processed for plasmid 
extraction. 
Digestion with BtsI was employed to test for presence of the A to C transversion in the 
miR-34a site .The exon 11 reporter plasmid harbors four sites for the BtsI which upon 
digestion is expected to produce two major products and 2 minor products indicating no 
loss of the BtsI sites. However successful mutation of A to C is expected to lead to loss of 
one of the BtsI site in the miR-34a seed region hence digestion with Bts1 is now expected 
to give one major product and 2 minor products (Figure 25B). 
A digestion reaction of the newly obtained plasmids expected to harbor the mutation and 
the original exon11 plasmid with the restriction endonuclease BtsI was set up by 
incubation at 550C for 60 minutes. BtsI is a very sensitive enzyme hence the BtsI was 
diluted in NEB4 buffer as the glycerol present in enzyme mix itself may prevent specific 
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cutting of the plasmid. The reaction was set using 1ug of plasmid DNA with 1 unit of BtsI 
and 1:10 diluted BSA (1 µg/µl) added at 1 µl per 10 µl of total reaction volume. This 
managed to solve the problem as we obtained the expected products for both the exon11 
(2 major products at the expected size range) and the suspected mutants (single product 
at ~6000bp) (Figure 25C). Hence one of them was used for the further reporter assays. 
 
Reporter assay to check for responsiveness of exon11 mutant reporter (exon 
11 A>C) to miR-34a regulation. 
 
For this MCF7 cells were transfected with anti-miR-34a and co transfected with either 
empty psicheck2 vector or exon11 A>C plasmid. The control cells were transfected with 
just the empty psicheck2 or exon11 A>C plasmid. 24 hours post transfection cell were 
processed for obtaining the lysates. These lysates were used for performing the reporter 
assay (Figure 26A). 
 
Similarly H1299 cells were transfected with miR-34a and cotransfected with empty 
psicheck2 vector or exon11 A>C. The control cells were transfected with miR-34a mut  
and cotransfected with psicheck2 or exon11 plasmid A>C. 24 hours post transfection cell 
were processed for obtaining the lysates. These lysates were used for performing the 
reporter assay (Figure 26B). 
It was seen in both the cell lines the mutant reporter showed similar activity as compared 
to the empty vector. It was also seen that the mutant reporter showed similar activity in 
response to anti-miR-34a treated or untreated conditions in MCF7 cell line and miR-34a 
overexpression or miR-34a mut expression in H1299. Hence it was seen with the 
presence of A>C transversion responsiveness to miR-34a was indeed abolished. 
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 A)                        5‟ cuccaCGUCUGAUAUCACUGCCa 3' MDM4  
                             5‟ cuccaCGUCUGAUAUCCCUGCCa 3' MDM4 
                             3'  uguugGUCGAUUCUGUGACGGu 5' hsa-miR-34a 
 
B) 
 
 
C) 
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Figure 25: Site directed mutagenesis A) Schematic of the miR-34a seed 
region in exon11 in presence and absence of the A to C tranversion. 
B) Plasmid map showing restriction digestion sites for psicheck2+444bp and 
psicheck2+444bp with A>C transversion.   
C) Digestion of the plasmids with BtsI by using extremely specific digestion 
conditions. The reaction was set using 1ug of plasmid DNA with 1 unit of BtsI 
and 1:10 diluted BSA added at 1 µl per 10 µl of total reaction volume. All the 
products were analysed on a 1% agarose gel. 
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Figure 26: Effect of miR-34a on exon 11 A>C reporter. A) Effect of 
inhibition of endogenous miR-34a on expression of exon11 A>C reporter. MCF7 
cells were transfected with anti-miR-34a and cotransfected with either empty 
psicheck2 or exon11 A>C. Control cells were transfected with empty psicheck2 
or exon11 A>C. 24 hours post transfection cells were processed for obtaining 
lysates and relative luciferase activity was measured. Error bars represent 
results from six independent experiments. 
 
B) Effect of overexpression miR-34a on expression of exon11 A>C reporter. 
H1299 cells were transfected with miR-34a and cotransfected with either empty 
psicheck2 or exon11 A>C. Control cells were transfected with miR-34amut and 
cotransfected with empty psicheck2 or exon11 A>C. 24 hours post transfection 
cells were processed for obtaining lysates and relative luciferase activity was 
measured. Error bars represent results from six independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 
 
 
 
Detection of HDMX-L transcripts in response to cisplatin treatment. 
 
 
It is known that the activity of p53 is kept under check by two of its important negative 
regulators MDM2 and MDM4 (HDMX). An interesting negative feedback loop exists 
between p53 and MDM2 where p53 activates MDM2 and MDM2 in turn inhibits the 
activity of p53 either by inhibition of transcription of p53 or by ubiqutin mediated 
proteasomal degradation of p53. Hence MDM2 is known to be activated by p53 but no 
such report was available for MDM4. However, recently it was shown that HDMX might 
contain a potential p53 inducible promoter P2 in its first intron (Figure 27A). It was 
shown that in response to DNA damage agent leading to p53 activation production of a 
novel HDMX-L transcript from the P2 promoter is observed. It was also shown that this 
mRNA transcript is more efficiently translated than the transcript from the constitutive 
P1 promoter and codes for a longer form of the protein (Philips 2010). 
It was also shown that 10 µM cisplatin treatments of ovarian cancer cells led to an 
increase in transcription from the HDMX-P2 promoter over a period of 24 hours and in 
comparison to transcription from the HDMX constitutive promoter (Figure 27B). 
 
 
 
 
 
 
 
 
 
70 
 
 
A) 
 
B) 
 
 
Figure 27: Schematic of the HDMX promoter region and the effect 0f 
cisplatin on transcription from these promoters A) A novel promoter in 
intron 1 of HDMX contains a functional p53 binding site. A map of the 5′-end 
of the HDMX gene, showing the position of the novel exon 1β. A potential p53-
binding site in intron 1 is compared with the consensus p53-binding 
sequence. Inverted triangles show the known translation start site in exon 2 
and an in-frame ATG in exon 1β, initiation of translation from which would 
incorporate 18 additional amino acids at the N terminus of HDMX. 
B) Effect of 10 µM cisplatin on transcription from HDMX-P2: OAW-42 ovarian 
cancer cells that express wild-type p53 were exposed to 10 μM cisplatin for the 
indicated times before being prepared for analysis by quantitative RT-PCR. 
Phillips A et al (2010) HDMX-L is expressed from a functional p53-responsive 
promoter in the first intron of the HDMX gene and participates in an 
autoregulatory feedback loop to control p53 activity. J Biol. Chem. 
285(38):29111-27 
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We sought to analyse the presence of this new transcript from the promoter P2 by 
quantitative RT-PCR using the forward primer 5'-TGTTTCAGCCTTCACCTGAG-3' and 
reverse primer 5‟-AGATCCTGCAAGCACTGTCA-3‟ specific for the HDMX-P2 transcript. 
MCF7 cells were treated with 10µM cisplatin and untreated MCF7 cells were used as 
control. 24 hours post treatment RNA was extracted, reverse transcribed and qRT-PCR 
analysis was performed. 
 
From the analysis of the amplification plot which plots fluorescence vs cycle number it 
could be seen that low quantity of transcript from exon 1β (HDMX-P2) was present in 
the untreated MCF7 cells as higher the cycle number lower is the initial amount of 
mRNA transcript present. However there is no increase the production of transcript 
from exon 1β (HDMX-P2) in the presence of 10 µM cisplatin (DNA damage agent which 
would lead to p53 activation).Hence we could not verify the report on role of p53 in the 
activation of transcription from the alternative promoter P2 in the intron of the HDMX 
gene (Figure 28). 
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Figure 28: Amplification plot for Exon 1β and GAPDH in absence and 
presence 10 µM cisplatin.  MCF7 cells were treated with 10µM cisplatin. 24 
hours after treatment RNA was extracted, reverse transcribed and qRT-PCR 
analysis was performed in quadruplicates. 
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IV. DISCUSSION 
 
 
It is known that p53 is mutated or deleted in 50% of cancers contributing toward tumor 
development. However, in cancers retaining the wild type p53 it was realized there were 
certain other factors responsible for mediating tumor formation. Against this 
background the critical negative regulators of p53 viz. MDM2 and MDM4 gained 
attention. It was found that these two proteins were overexpressed in many cancers 
retaining wild type p53. MDM4  in fact is overexpressed in several types of cancers that 
retained wild-type p53 including gliomas, a number of pre-B acute lymphoblastic 
leukemias, tumor cell lines, and some primary tumors including breast tumors, head and 
neck squamous cell carcinomas, and retinoblastomas (Gilkes 2008). 
 
In normal unstressed cells MDM4 and MDM2 keep the activity of p53 in check. 
However, under conditions of stress these two proteins undergo modifications that play 
a role in relieving the repression off p53 (Shafdan 2012). Hence the inhibition of 
expression of these negative regulators is considered essential for reactivation of p53.  
 
Initially it was thought that with constitutive transcription little control was imposed on 
transcription of MDM4 (maybe through transcription factor binding). There were also  
reports of an alternative form of MDM4 being transcribed from a novel p53 responsive 
promoter in the first intron of MDM4 gene . However, we were unable to verify the 
report of production of this alternative form of MDM4 (Figure 28). Post transcriptional 
regulation was also not extensively looked into as a possible mechanism for regulation of 
MDM4 expression. With previous studies it was shown that genotoxic stress led to a 
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decrease in full length MDM4 transcripts (Markey 2008) Alternative splice variants of 
MDM4 in response to genotoxic stress were also reported (Chandler 2006) but their 
production could not completely compensate for  the decrease in full length MDM4 that 
was observed (Figure 7). Having explored several factors to address this downregulation 
there was preliminary evidence of possible role of microRNAs in regulation of MDM4 
expression. The microRNAs as small non coding RNA molecules involved in the post 
transcriptional regulation of gene expression have received attention in the recent years 
(Bartel 2004). In case of the tumor suppressor p53 the miR-34 family is considered 
important as the members of this family are direct transcriptional targets of p53 and aid 
the tumor suppressive function of p53 (Hermeking 2010). 
There was evidence of inverse correlation between MDM4 levels and miR-34a levels in 
MCF7 cells (Figure 8). Computational analysis also showed presence of several miR-34a 
binding sites in the 3‟UTR. However the mechanism for the down regulation had not 
been determined. 
 
We wanted to analyse the potential role of miR-34a in regulation of MDM4. On analysis 
of cells of different origins and varying p53 status it was seen that upon DNA damage viz. 
treatment with doxorubicin miR-34a was induced in H1299 and MCF7  accompanied by 
a decrease in MDM4 expression(Figure 9). IMR90 and U2OS expressed high levels of 
miR-34a and though there was no induction of miR-34a there was decrease in MDM4 
expression in these two cells following damage indicating role of alternative mechanisms 
in control of MDM4 expression. In case of SAOS2 where induction of miR-34a upon 
damage was accompanied by increase in MDM4 expression we speculate involvement of 
other factors in regulation of expression. The presence of a human single nucleotide 
polymorphism which is expected to render MDM4 unresponsive to miR-34a regulation 
was checked however this SNP was absent in the SAOs2 cell line. It could also be possible 
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that this cell line maybe incompetent for microRNA mediated regulation. Hence, it was 
seen that depending on the cell line different mechanisms may impact MDM4 
expression, regulation by miR-34a being one of them (Figure 9). 
 
The effect of miR-34a on MDM4 was verified by comparing the response of MDM4 and 
CDK6 and CCND1 (known targets of miR-34a) to downregulated or elevated levels of 
miR-34a. It was seen that both in case of overexpression of miR-34a or inhibition of 
miR-34a the response of MDM4 was comparable to the response of CDK6 and CCND1 
(Figure 10A, 11A). This impact was also biologically significant as seen from the 
downregulation of protein levels of MDM4 in response to elevated levels of miR-34a or 
increase in protein levels in response to inhibition of endogenous miR-34a. Since 
microRNAs are responsible for subtle changes in gene expression we could observe only 
a modest impact on MDM4 protein expression (Figure 10B, 11B). Hence it could be seen 
that miR-34a led to modulation of MDM4 expression leading to differences in the 
protein expression. This indicated that mir-34a may be directly involved in regulation of 
MDM4. 
 
However the 3‟UTR of MDM4 which was seen to harbor potential miR-34a binding sites 
was unresponsive to miR-34a regulation as seen with the reporter assays performed 
using 1700bp region of the 3‟UTR cloned in a reporter plasmid (Figure 14). 
Since there was an effect on MDM4 expression in presence of miR-34a and to address 
the possibility of indirect effect of miR-34a on MDM4 expression instead of direct 
binding a reassessment of MDM4 mRNA was performed using August 2010 release of 
MiRanda . It predicted a miR-34a regulatory site in the protein coding exon 11 of MDM4. 
It was possible that the older software was not able to detect this site as it is not 
programmed include sites in the coding region but only the ones in 3‟UTR. Experimental 
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evidence has accumulated showing that microRNA (miRNA) binding sites within protein 
coding sequences (CDSs) are functional in controlling gene expression viz miR29 and 
miR-15  differentially expressed in postnatal aortic development downregulate elastin via 
3' UTR and coding-sequence binding sites (Ott 2011). 
 
This has prompted researchers to develop algorithms that include both coding region 
sequences and 3‟UTR sequences resulting in higher sensitivity of target site prediction. 
As seen with a larger scale study which showed that more than a thousand genes 
expected to be microRNA targets  did not contain microRNA binding sites in the 3‟UTR  
and these were thus not recognized by existing miRNA target prediction programs. 
(Reckzo 2012). 
 
This new site found in the exon 11 of MDM4 was further cloned into a reporter vector 
and used to test its functionality (Figure 20). Reporter assays under similar conditions of 
overexpression and inhibition of miR-34a led to modulation of reporter activity verifying 
a direct role of miR-34a in regulating expression of MDM4 via binding of miR-34a to this 
new site in the exon 11 (Figure 22, 24). 
This MDM4site is of the most highly conserved type, 8mer-Al with miRSVR score -1.286 
which places this site in the top 2.5% of the predicted sites (Betel 2010). The predicted 
region was also seen to match the seed sequences of CDK6 and CCND1 (Sun 2008). It 
was also seen that the structurally homologous MDM2 possesses a different codon in the 
same region therefore MDM2 is expected to be unresponsive to miR-34a regulation. 
 
The mir-34a site in exon 11 is also a site for a human single nucleotide polymorphism 
(SNP) which causes an A to C transversion. It is suspected that the presence of this point 
mutation would disrupt the miR-34a seed region and thereby render it unresponsive to 
77 
 
miR-34a regulation. We confirmed this with reporter assays involving the use of 
plasmids with the point mutant (Figure 26). All our cell lines were also screened for the 
presence of this allele however they were found to possess the majority A allele. However 
the presence of the SNP would need consideration and screening in case of cell lines 
unresponsive to miR-34a regulation. This would also play an important role in 
therapeutic intervention by miR-34a as a subset of population might be unresponsive to 
miR-34a owing to the presence of this SNP. It was also reported that microRNA target 
sites in coding regions require a perfect binding along the miRNA seed region and 
mismatches disrupt their functionality (Reckzo 2012). 
 
Significance of microRNA regulatory sites in the coding region? 
 
There is increasing evidence of microRNA target sites in the coding region which are 
seen to play a role in controlling gene expression (Reckzo 2012). Hence it is worth 
focusing on the significance of this phenomenon observed.   
There are reports of a positional bias in the location of these target sites in the coding 
region with these sites located at the end of the coding region and the beginning of the 
3‟UTR. These sites towards the very 3‟ end of the transcript are more likely to be 
functional and evolutionarily conserved (Forman 2010). 
 
From the point of view of evolution the sites in the 3‟UTR have less selective pressure, as 
these sites can be created and mutated without affecting the functionality of an encoded 
protein. Many of these sites can be eventually be lost in the process of evolution (Lu 
2008). For microRNA recognition sites in coding regions, mutations in the target site 
that lead to formation of a less efficient protein will be selected against and not find its 
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way in the population. This would lead to less likelyhood of variation in the microRNA 
target sites. 
 
Another factor playing a role in localization of these sites in the coding region is the 
presence of polyadenylation signals. In case of presence of alternative polyadenylation 
signals there could be different lengths of 3‟UTRs under different conditions which in 
some case could lead to elimination of microRNA regulatory sites (Selbach 2008).  As 
opposed to this the sites in the coding region would be present irrespective of the 
presence of these alternative polyadenylation signals making it less vulnerable to change 
in cellular conditions (Lytle 2007). Making coding region microRNA target sites a more 
consistent form of regulatory mechanism. 
Another level of regulation can be achieved through the splicing mechanism which could 
lead to inclusion or exclusion of these regulatory sites in the exon in a particular splice 
variant. This could potentially impose differential control on the various splice variants 
of a particular gene. For instance the exon 11 of MDM4 is retained in all of its known 
transcript variant making all the transcripts possible targets of miR-34a mediated 
regulation (Gu 2009). 
There were also some reports indicating the influence of the length of the 3‟UTR to the 
presence of microRNA binding sites in the coding region. In a study involving the use of  
DIANA-microT-CDS algorithm on comparing the length of the 3‟UTR with coding region 
scores for microRNA binding  it was see that genes with 3‟UTR of  less than 500nt  
length  have a significantly higher CDS target score .  This indicates that the length of the 
3‟UTR also creates a bias in the possible presence of these sites in the coding region 
(Reckzo 2012). 
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Future studies 
Recent studies with MDM2 have shown that not only the primary amino acid   sequence 
but also the length of C terminal tail present after the RING domain plays an important 
role in MDM2 activity (homodimerization and heterodimerization). The sequence of the 
C terminal tail is evolutionarily conserved. The sequence and length of the C terminal tail 
is also conserved in case of MDM4 protein. To see if there is possibility of translation 
into the 3‟UTR which may alter the C terminal tail length and sequence thereby affecting 
its activity (Dolezelova 2012) 
This work paves way for future directions of this project. The regulation of MDM4 
mRNA was not due to microRNA binding sites in the 3‟UTR. Based on existing reports 
the length of the 3‟UTR needs assessment  which will aid in identification of the exact 
role of 3‟UTR of MDM4.  To begin with we have started looking for the presence of 
3‟UTR variants by 3‟Rapid amplification of cDNA ends (3‟RACE). If there exist such 
variants we would want to identify their sequences and look for regulatory sites and 
signals which may aid understanding of translation of MDM4 protein. 
 
The long term application of this study would in terms of potential clinical application to 
assess the efficacy of miR34a mediated downregulation of hdmx in combination with 
MDM2/HDM2 inhibitors directed towards reactivation of p53. 
Of late, restoration of p53 function as a therapeutic approach has gained attention. 
Inhibition of MDM2 and MDM4 has been explored as a strategy for reactivation of p53 
in tumors. Unfortunately, inhibition of MDM2 leads to activation of p53 not only in 
cancer cells but also normal cells leading to lethal side effects. However, it was shown 
that complete inhibition of MDM4 is relatively transient and a less toxic and hazardous   
strategy. Although it was seen that transient activity in absence of MDM4 may damage 
lymphoid organs and bone marrow its effect on the intestinal epithelium arguably a 
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critical tissue is very mild. It was seen in mouse studies that with intestinal integrity 
preserved all effects arising from activation of p53 in absence of MDM4 are reversible 
leading to increase in long term survival of mice. This was particularly seen to be 
effective in treatment of a lymphoma model (Garcia 2011). 
 
There are two strategies that can be adopted in order to inhibit activity of MDM4 in 
cancer. First would be the use of small molecule inhibitor which would relieve the 
MDM4 dependent inhibition of p53 and help in restoration of p53 function. In the 
absence of optimal MDM4 antagonists, an alternative approach using existing MDM4 
antagonists in combination with agents that sensitize cells to p53-dependent apoptosis 
would help in restoration of p53 (Wade 2009). 
 
The second approach of using combination therapy is gaining attention. Although agents 
(e.g., Nutlin-3a) that disrupt MDM2-p53 interaction can inhibit tumor growth, they are 
less effective in cancer cells that express high levels of MDM4. There are reports of  a 
benzofuroxan derivative (7-(4-methylpiperazin-1-yl)-4-nitro-1-oxido-2,1,3-
benzoxadiazol-1-ium, NSC207895)  that could inhibit MDM4expression in cancer cells 
Treatments of MCF-7 cells with this small-molecule MDM4 inhibitor activated p53, 
resulting in elevated expression of proapoptotic genes (e.g., PUMA, BAX, and PIG3). 
Importantly, this novel small-molecule p53 activator caused MCF-7 cells to undergo 
apoptosis, and acted additively with Nutlin-3a to activate p53 and decrease the viability 
of cancer cells (Wang 2010). In another study combined treatment with Nutlin and ABT-
737 (a small molecule BH3 mimetic significantly increased apoptosis compared to either 
agent alone in cells with high levels of MDM4. This particular combination has also 
proven effective in primary isolates from AML patients (Wade 2009). 
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 Recently it was also shown that SAH-p53-8 (small alpha helical peptide ) which targets 
MDM4 in cells and blocks formation of the p53-MDM4interaction, thereby restoring the 
p53 pathway(Bernel 2010)) in combination with nutlin was a successful combination in 
sensitization of melanoma. Most melanomas have high levels of MDM4 and low levels of 
MDM2 and hence responded poorly to nutlin 3 treatments. However, these cells were 
sensitive to treatment with SAH-p53-8 indicating its effectiveness in induction of p53 in 
these cells. It was also seen that melanoma cells with high MDM4/MDM2 were sensitive 
to either SAH-p53-8 or nutlin-3 but even more sensitive to combination treatment 
(Bernal 2010). This validates the development of specific targeted therapy for MDM4 
which in combination with MDM2 inhibitors can work towards effective reactivation of 
p53. 
In terms of exploring the therapeutic potential of miR-34a several animal studies have 
indicated successful tumor volume reduction or induction of apoptosis with use of miR-
34a. In a study involving use of mice with lung metastasized tumors a 50% reduction in 
tumor volume was observed upon intravenous delivery of miR-34a.  In another study an 
increase in apoptosis was observed upon increased levels of miR-34a in a similar lung 
cancer model (Bader 2012). In a model of subcutaneous and orthotopic miaPACA 
pancreatic xenografts a systemic delivery of miR-34a was accompanied with reduction in 
tumor burden and increase in necrosis and apoptosis (Pramanik 2011). Similarly in 
xenograft models of non small cell lung cancer miR-34a administration led to increase in 
apoptosis and reduction in proliferation (Bader 2012). The success of miR-34a 
overexpression in animal models warrants its use to be tested for human studies. 
One of the challenges for the transition of miR-34a based therapies from bench to 
bedside is the selection of an appropriate delivery system to ensure effective delivery of 
the therapeutic microRNA to the target tumors. The delivery technology with the best 
combination of efficacy, biodistribution, and safety was the NOV340 technology  
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(SMARTICLES Marina Biotech,Bothell, WA; MirnaTherapeuticsInc.,2011), an ionizable 
liposome that forms a particle with a diameter of ~120 nm.  The lipids and miRNA 
mimics are mixed under acidic conditions to facilitate efficient miRNA encapsulation 
and liposome formation. The pharmacology of the NOV340/miR-34a formulation was 
tested in an orthotopic model of hepatocellular carcinoma. It was seen that 
administration of this combination led to significant regression of existing tumors and 
prolonged their survival. The mice also appeared to be tumor free upon histologic 
examination (Bader 2012). 
 
Summary 
The results from the present study can be summarized as follows. 
 
 A relationship between miR-34a expression and MDM4 expression was 
established. 
  Interestingly, The 3‟UTR of MDM4 was unresponsive. 
  Analysis revealed the presence a functional miR-34a regulatory site in the exon 
11 region of MDM4. 
  However a subset of the population/cell lines may be unresponsive to miR-34a 
regulation due to the presence of the „C‟ allele. 
 This validates further work in the direction of exploring the potential of miR-34a 
as therapeutic for MDM4 inhibition in tumors overexpressing MDM4 and 
retaining wild type p53. 
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